resistant hypertension: necesidades para iniciar un programa denervacion - dr. luis miguel ruilope...

18
Resistant hypertension: NECESIDADES PARA INICIAR UN PROGRAMA DE DENERVACION Luis M Ruilope

Upload: shci-seccion-de-hemodinamica-y-cardiologia-intervencionista

Post on 07-May-2015

353 views

Category:

Health & Medicine


0 download

DESCRIPTION

Presentación del Dr. Luis Miguel Ruilope Urioste, del Hospital Universitario 12 de Octubre de Madrid, durante la I Reunión de Denervación Renal de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de la Sociedad Española de Cardiología (SEC), celebrada del 29 al 30 de enero de 2014.

TRANSCRIPT

Page 1: Resistant hypertension: Necesidades para iniciar un programa denervacion - Dr. Luis Miguel Ruilope Urioste

Resistant hypertension: NECESIDADES PARA INICIAR UN PROGRAMA DE DENERVACION

Luis M Ruilope

Page 2: Resistant hypertension: Necesidades para iniciar un programa denervacion - Dr. Luis Miguel Ruilope Urioste

GRADES OF BP AS DEFINED BY CURRENT GUIDELINES

• OPTIMAL BP < 120/80 mmHg

• NORMAL BP 120-129/80-84 mmHg

• HIGH-NORMAL BP 130-139/85-89 mmHg

• GRADE 1 HYPERTENSION 140-159/90-99 mmHg

• GRADE 2 HYPERTENSION 160-179/100-109 mmHg

• GRADE 3 HYPERTENSION > 180/110 mmHg

• ISH > 140/< 90 mmHg

• RESISTANT HYPERTENSION

• MALIGNANT HYPERTENSION

Page 3: Resistant hypertension: Necesidades para iniciar un programa denervacion - Dr. Luis Miguel Ruilope Urioste
Page 4: Resistant hypertension: Necesidades para iniciar un programa denervacion - Dr. Luis Miguel Ruilope Urioste

Other definitions

• Controlled hypertension (<140/90 mmHg)

requiring 4 or more drugs can be

considered as resistant while refractory

hypertension should be that present in

patients requiring 5 or more drugs in the

absence of adequate control.

Calhoun D et al, Circulation 2008.

Page 5: Resistant hypertension: Necesidades para iniciar un programa denervacion - Dr. Luis Miguel Ruilope Urioste

EXCLUSION OF

PSEUDORESISTANCE

• THE ROLE OF ABPM AND

HBPM IN THE CORRECT

DIAGNOSIS OF

RESISTANT

HYPERTENSION

Page 6: Resistant hypertension: Necesidades para iniciar un programa denervacion - Dr. Luis Miguel Ruilope Urioste

Frequency of Resistant Hypertension

in Treated Hypertensives: Spain

de la Sierra A et al. Hypertension. 2011;57:898-902.

Treated Patients With

Hypertension

Resistant Hypertension

(12.2% of total

treated population)

True resistant

hypertension

(7.6% of total treated

population)

White-coat

hypertension

(4.6% of total treated

population)

Page 7: Resistant hypertension: Necesidades para iniciar un programa denervacion - Dr. Luis Miguel Ruilope Urioste

Proportion of patients diagnosed as having Refractory hypertension with

normal ABPM values

• Daytime BP < 135/85 mmHg

– 44.1%

• 24-hour BP < 130/80 mmHg

– 37.5%

• Nighttime BP < 120/70 mmHg

– 31.8%

Page 8: Resistant hypertension: Necesidades para iniciar un programa denervacion - Dr. Luis Miguel Ruilope Urioste

TOD and CVD in patients with True (24-h BP

> 130 and/or 80 mmHg) or isolated-office

(24-h BP < 130/80 mmHg) Refractory

hypertension

TOD CVD0

5

10

15

20

25

30

35

True RH

I-O RHp<0.001

p<0.001

%

Page 9: Resistant hypertension: Necesidades para iniciar un programa denervacion - Dr. Luis Miguel Ruilope Urioste

Incidence of RH in new hypertensives

• In new hypertensives, 2% present with RH after 18 months of pharmacological therapy

• Development of RH is followed by a 50% increase in risk of suffering CV events or death

• It takes place after similar duration of arterial hypertension. There must be a factor accelerating CV and probably renal damage in RH.

Daugherty et al, Circulation 2012

Pimenta & Calhoun, Circulation 2012

Page 10: Resistant hypertension: Necesidades para iniciar un programa denervacion - Dr. Luis Miguel Ruilope Urioste

FACILITATORS OF BP UNRESPONSIVENESS TO STANDARD THERAPY

• Clinical inertia

• Poor compliance

• Inadequate diet (salt)

• Inadequate and late use of combinations

• Primary aldosteronism (10-12%)

• Inadequate control of SNS activity

• BP variability

• OSA

• Diabetes and obesity

• CKD

• Progression of arterial disease due to an inadequate BP control

Solini a & Ruilope LM. Nat Rev Cardiol 2013

Page 11: Resistant hypertension: Necesidades para iniciar un programa denervacion - Dr. Luis Miguel Ruilope Urioste

WHY DOES RH DEVELOP?

• IS THIS A PHENOTYPE?

• IS IT THE CONSEQUENCE OF MAINTAINEDLY UNCONTROLLED BLOOD PRESSURE LEVELS?

Page 12: Resistant hypertension: Necesidades para iniciar un programa denervacion - Dr. Luis Miguel Ruilope Urioste

“neurogenic hypertension” - 10% of RH patients could

constitute a phenotype characterized by an increased heart rate and high levels of plasma aldosterone

David Calhoun, ISH, Sydney, 2012

Page 13: Resistant hypertension: Necesidades para iniciar un programa denervacion - Dr. Luis Miguel Ruilope Urioste

Dzau et al. Circulation 2006;114:2850–70

Mancia et al. J Hypertens 2007;25:1105–87

Risk factors lead to increasing risk of organ damage

and clinical events: The cardio-renal continuum

● The risk associated with maintainedly elevated BP is greatly

magnified by other CV risk factors, e.g.:

– Hyperlipidaemia

– Diabetes

– LVH

– CKD

– Increased arterial stiffness

● The presence of such risk factors initiates pathological events and

processes like oxidative stress and endothelial dysfunction which

ultimately lead to overt organ damage and failure

● BP can become unresponsive as a consequence of the

maladaptation of the vessels (increase in peripheral resistances and

arterial stiffness)

Page 14: Resistant hypertension: Necesidades para iniciar un programa denervacion - Dr. Luis Miguel Ruilope Urioste

Exclude

Pseudoresistance

Identify and Reverse

Contributing Lifestyle

Factors

Discontinue or Minimize

Interfering Substances

Screen for Secondary

Causes of HT

Pharmacologic

approach:

# adherence

Diagnostic and Treatment

Algorithm of RH

Schmieder 2012

Page 15: Resistant hypertension: Necesidades para iniciar un programa denervacion - Dr. Luis Miguel Ruilope Urioste

Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz, Parati

G, Ruilope L, van der Borne P, Tsioufis C. ESH POSITION PAPER: RENAL

DENERVATION-AN INTERVENTIONAL THERAPY OF RESISTANT

HYPERTENSION. J HYPERTENS (IN PRESS)

• Hypertensive patients are elegible for RDN if

they have treatment resistant hypertension

defined by office SBP >= 160 mmHg (150

mm Hg if type 2 diabetes) despite treatment

with 3 or more drugs og different types in

adequate doses, including one diuretic, which

is equivalent to stage 2 or 3 hypertension.

• Patients should be evaluated by a

hypertension specialist.

Page 16: Resistant hypertension: Necesidades para iniciar un programa denervacion - Dr. Luis Miguel Ruilope Urioste

RESULTS ADEQUATE

INTERVENTION IN RH

• N=197 RH patients with SBP > 160 mmHg

• ABPM normal in 108 (pseudoresistant)

• Spironolactone administered to 75 good

response in 60 (80%)

• Remaining 29 (14 intolerant to spiro), 18

responded to other combinations

• 11 (12.3%) were denervated

Fontela A et al, Rev Esp Cardiol 2012

Page 17: Resistant hypertension: Necesidades para iniciar un programa denervacion - Dr. Luis Miguel Ruilope Urioste

True resistant HTN non responders to spironolactone

Δ Office BP (final vs baseline)

Post-Spironolactone Post-Aliskiren 300 mg

+3 mmHg

-9 mmHg*

-30

-25

-20

-15

-10

-5

0

5

Office Diastolic BP

P< 0.004

+1 mmHg

-28 mmHg* -30

-25

-20

-15

-10

-5

0

5

Office Systolic BP

P<0.005

*p<0.05 for differences between post- and pre-aliskiren therapy

Segura J.et al., J Am Soc Hypertension 2011

Page 18: Resistant hypertension: Necesidades para iniciar un programa denervacion - Dr. Luis Miguel Ruilope Urioste

CONCLUSIONS

1- RH IS A PREVALENT PROCCESS

2- ADEQUATE INTERVENTION DEFINES

AND CONTROL THE MAJORITY OF CASES

3- IDEALLY THREE PARTNERS INTERVENE IN

THE PROCCESS: PRIMARY CARE,

HYPERTENSIOLOGIST AND INTERVENTIONIST

4- RDN IS REQUIRED IN 10-15% OF THE

CASES